French deep-tech company SeqOne has entered into a definitive agreement to acquire Congenica, the UK-based digital health company spun out of the Wellcome Sanger Institute. 

The acquisition unites SeqOne’s AI-powered platform for Next-Generation Sequencing (NGS) analysis with Congenica’s clinical decision support technology and clinical interpretation services. Together, the integrated platform will accelerate rare disease diagnosis and enable more precise, personalised cancer therapies by transforming complex genomic data into rapid, actionable insights.

Founded in 2012, Congenica has deep clinical expertise and experience servicing over 25 private and public labs, including multiple NHS Genomics Laboratory Hubs and national initiatives such as Genomics England and the Hong Kong Genomic Programme.

SeqOne, an AI-powered genomic analysis platform, provides clinical decision-support tools that enable molecular laboratories to deliver fast, accurate, and scalable analysis of genetic data for applications in oncology, rare and inherited diseases, and infectious diseases.

The acquisition comes at a critical inflection point in medicine. While the cost of sequencing a human genome has plummeted, hospitals and labs face an “interpretation bottleneck”—the single biggest barrier to delivering personalised medicine. SeqOne believes this challenge can only be solved with highly intelligent software.  

“The rapid pace of personalised medicine demands continuous investment in software innovation and deep specialisation. By integrating Congenica’s world-class team, we are further enhancing our strong growth trajectory and ability to provide market-leading software to customers, expert interpretation services, and deepening our presence in the UK market - a global leader in clinical genomics since the landmark 100,000 Genomes Project,” said Martin Dubuc, CEO of SeqOne.

The combined entity will have a significantly expanded global footprint, serving over 160 customer laboratories in more than 30 countries, and enabling over 200,000 patient genomic analyses in 2025 - a threefold increase over 2024.

“Congenica has been an instrumental partner to Genomics England, particularly in advancing rare disease diagnosis through their robust platform for clinical whole genome analysis. We look forward to continuing this important work with the combined expertise of the SeqOne team to deliver benefits for patients,” said Dr. Richard Scott, CEO at Genomics England.

Dr Andy Richards CBE, Chairman of Congenica, added, “We support this combination with SeqOne, believing their vision and resources are best positioned to carry that legacy forward and ensure our innovative platform continues to thrive and serve patients globally.”

The acquisition follows a period of intense organic growth for SeqOne, which doubled its revenue and expanded its international presence from three to over 30 countries in just 12 months. It also builds on its April acquisition of Life & Soft, extending capabilities into multi-omics and virology.